Leukocytoclastic Vasculitis Secondary to NSAIDs

Evidence from Guidelines and Drug Labels

• The EULAR gout management guidelines explicitly document leukocytoclastic vasculitis (LCV) as a recognized adverse effect of allopurinol exposure, establishing precedent that drug-induced LCV is a documented phenomenon in rheumatologic medications 1
• The 2022 Drug Allergy Practice Parameter from the American Academy of Allergy, Asthma, and Immunology confirms that NSAIDs cause delayed hypersensitivity reactions occurring >6 hours after dosing, many of which are T-cell mediated, and notes that NSAIDs are among the most common causes of various cutaneous drug reactions 2

Critical Pitfalls to Avoid

• Do not rechallenge with the same NSAID or potentially cross-reactive NSAIDs once LCV is confirmed, as this represents a serious hypersensitivity reaction 2
• NSAIDs can cause both cross-reactive hypersensitivity (affecting multiple NSAIDs through COX-1 inhibition) and drug-specific allergic reactions 2
• For patients with confirmed NSAID-induced LCV, avoid all NSAIDs until formal allergy evaluation, as the pattern of cross-reactivity in vasculitic reactions is not well-established 2
• Document the reaction clearly in the medical record as a serious drug hypersensitivity to prevent future re-exposure 2